Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02411565 · ClinicalTrials.gov registry record · Early Phase 1
Fermented Wheat Germ Extract in Women With Ovarian Cancer
A Early Phase 1 study, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 3
- Enrollment target
NCT02411565 is a Early Phase 1 study that was terminated before completion, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 3 participants.
The verdict
NCT02411565, a Early Phase 1 study, was terminated before completion, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
The main purpose of this Pilot Study is to test the safety, tolerability and quality of life in women who take Fermented Wheat Germ Extract (FWGE), to determine if an active form of FWGE can be detected in the blood, and determine whether short-term therapy with FWGE has any effect on the tumor marker, cancer antigen 125 (CA-125).
Interventions
- DRUG Placebo
- DRUG Fermented Wheat Germ Extract (FWGE)
- OTHER Standard of Care: Planned Surgery
- OTHER Quality of Life (QoL) Surveys: FACT-O
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2016-03-01 |
| Est. Completion | 2018-01-08 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02411565
The ClinicalTrials.gov registry entry for NCT02411565 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is H. Lee Moffitt Cancer Center and Research Institute, which has 502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT02411565 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02411565 about?
NCT02411565 is a clinical study titled "Fermented Wheat Germ Extract in Women With Ovarian Cancer". The main purpose of this Pilot Study is to test the safety, tolerability and quality of life in women who take Fermented Wheat Germ Extract (FWGE), to determine if an active form of FWGE can be detected in the blood, and determine whether short-term therapy with FWGE has any effect on the tumor mark...
What is the current status of trial NCT02411565?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 3 participants. The study started on 2016-03-01. Estimated completion is 2018-01-08.
What interventions are being tested in trial NCT02411565?
The interventions under investigation include: Placebo (DRUG), Fermented Wheat Germ Extract (FWGE) (DRUG), Standard of Care: Planned Surgery (OTHER), Quality of Life (QoL) Surveys: FACT-O (OTHER).
Who is sponsoring clinical trial NCT02411565?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.